Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 191

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 191
---
 or conflict with any covenants with the Company; (ii amends the term of the Offer Letter, such that the Offer Letter terminated on December 31, 2024; and (iii) adjusts Boctor’s base salary from an annual rate of $350,000 to an annual rate of $280,000, effective as of October 16, 2024. Outstanding Equity Awards at 2024 Fiscal Year-End The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of December 31, 2024.

| ​               
 Name            | ​ 
 ​ | Option awards 
 Vesting       
 Commencement  
 date          | ​ |   Number of 
  securities 
  underlying 
 unexercised 
 options (#) 
 exercisable | ​ |     Number of 
    securities 
    underlying 
   unexercised 
   options (#) 
 unexercisable | ​ | Option    
 Exercise  
 Price ($) |       | ​ | Option     
 Expiration 
 Date       | ​ 
 ​ |
|:----------------|:--|:--------------|:--|------------:|:--|--------------:|:--|:----------|------:|:--|:-----------|:--|
| Fady Boctor     | ​ | 2/19/2021     | ​ |      21,567 | ​ |             — | ​ | $         | 37.40 | ​ | 2/19/2031  | ​ |
|                 | ​ | 12/21/2023    | ​ |      54,533 | ​ |        54,533 | ​ | $         |  1.41 | ​ | 12/21/2033 | ​ |
| Mitchell Arnold | ​ | 5/11/2021     | ​ |       5,000 | ​ |             — | ​ | $         | 32.10 | ​ | 5/11/2031  | ​ |
|                 | ​ | 12/21/2023    | ​ |      20,000 | ​ |             — | ​ | $         |  1.41 | ​ | 12/21/2033 | ​ |

Accounting and Tax Considerations Section 162(m) of the Code places a limit of $1,000,000 on the amount of compensation that a public company may deduct as a business expense in any year with respect to such company’s